We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
CEPI, the Coalition for Epidemic Preparedness Innovations, has joined with Korean biopharma firm SK Biopharma (SK) to develop a “variant-proof” vaccine that would protect against a large coronavirus subgenus that includes the SARS-CoV-2 virus that causes COVID-19. Read More
Eli Lilly’s IL-13 inhibitor lebrikizumab significantly improved disease severity when combined with topical corticosteroids in people with moderate-to-severe atopic dermatitis (AD) in the drug’s third pivotal phase 3 trial, the company said. Read More
The FDA has approved Amgen’s blockbuster Otezla (apremilast) as a treatment for adults with plaque psoriasis of any severity, making it the first oral therapy cleared for that indication. Read More
In a purchase aimed at broadening its portfolio of cancer therapies, Sanofi is acquiring San Francisco, Calif.-based Amunix Pharmaceuticals for $1 billion. Read More
Both companies cited the “Open Data Portal SARS-CoV-2 Variants and Therapeutics Activity Explorer,” hosted by the National Center for Advancing Translational Science. Read More
Ligelizumab, Novartis’ investigational anti-IgE antibody, didn’t stand up to the company’s established blockbuster omalizumab in a pair of phase 3 studies in patients with chronic spontaneous urticaria (CSU). Read More
The FDA has placed a partial clinical hold on Bluebird Bio’s gene therapy for sickle cell disease (SCD), lovotibeglogene autotemcel (lovo-cel), for trial participants under the age of 18 after a volunteer contracted persistent anemia. Read More